Loading interactive chart...
1DInterval:
Date Range
1 min
Advertisement
Aethlon Medical, Inc. (AEMD)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
As of 10:55AM EDT. Market open.
Mountain
Settings
- PR Newswire
Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for Santersus' NucleoCapture and HemoNucleoCapture devices.
- Insider Monkey
Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Call Transcript
Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Call Transcript February 14, 2024 Aethlon Medical, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Aethlon Medical Third Quarter Fiscal 2024 Earnings and Corporate Update. [Operator […]
- Zacks Small Cap Research
AEMD: Focus on Oncology Studies; In Vitro Binding Study Expected to Advance Clinical Trial Activities
By M. Marin NASDAQ:AEMD Moving forward towards oncology clinical studies in India & Australia Aethlon Medical (NASDAQ:AEMD) reported 3Q F24 results yesterday and provided a business update, as the company continues to advance research and clinical development activities for medical device, the Hemopurifier®. Under interim CEO James Frakes, the company’s long-standing CFO, AEMD has increased
Advertisement
Advertisement
Advertisement